Drug intelligence / Profile preview

RBV 002

Development stage: Preclinical
Lead developer: Revascular
Modality: Stem Cell Therapies → Cell Therapies

Overview

RBV 002 is a **preclinical allogeneic cell therapy** from Revascular being developed for **Hemophilia A**. The product is based on **CD157-positive vascular endothelial stem cells**, a regenerative vascular cell platform intended to restore or improve endothelial and vascular function. No specific molecular target, administration route, or explicit mechanism of action has been publicly disclosed, but the therapeutic rationale appears to be repair or replacement of dysfunctional vascular endothelial biology using donor-derived endothelial stem cells.

Other names: allogeneic vascular endothelial stem cells CD157+

Beyond the preview

Go deeper on RBV 002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBV 002.

Explore the full profile